CGC 11047: Clinical Trials

3 trials of CGC 11047, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 terminated. 2 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 12Completed 2
Phase 21Terminated 1

Follow CGC 11047: new trials by email Literature Review of CGC 11047 trials Research Report on CGC 11047

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety of 16.5 mg (3.3%) CGC-11047 Once Every 2 Weeks vs. Once Every 4 Weeks in Patients With CNV Due to AMD
CGC-11047 - Age Related Macular Degeneration
Phase 1CompletedProgen Pharmaceuticals432007-04-012012-08-06
Study of CGC-11047 in Patients With Metastatic Hormone Refractory Prostate Cancer
CGC-11047 - Prostate Cancer
Phase 2TerminatedUniversity of Wisconsin, Madison232006-06-012015-10-02
Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma
CGC-11047 and gemcitabine, CGC-11047 and docetaxel, CGC-11047 and bevacizumab - Cancer
Phase 1CompletedProgen Pharmaceuticals1722006-05-012016-07-21

Conditions studied

Lymphoma (1)  ·  Macular Degeneration (1)  ·  Neoplasm Metastasis (1)  ·  Neoplasms (1)  ·  Prostatic Neoplasms (1)

Sponsors

Progen Pharmaceuticals (2)  ·  University of Wisconsin, Madison (1)

Countries

United States (3)  ·  Mexico (1)  ·  Russia (1)

Top investigators

Joe Stephenson, MD (1)  ·  Peter Campochiaro, MD (1)